Showing items 406-430 of 4992 (200 Page(s) Totally)
<< < 12 13 14 15 16 17 18 19 20 21 > >>
View [10|25|50] records per page
| 國立成功大學 |
2024-09 |
Association of biomarkers with response to first-line (1L) vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in advanced head and neck squamous cell carcinoma (HNSCC): Results from KEYVIBE-005
|
Seo;S;Calderon;B;Chou;H-H;Hsu;C-H;Salman;P;Ghiringhelli;F;Ozyilkan;O;Rojas;C, I.;Sendur;M, A. N.;Tourneau, Le;C;Yen;C, J.;Shapira-Frommer;R;Rha;S, Y.;Zhang;Y;Chen;C;Pena;C, E.;Keenan;T;Chen;Y;Dettman;E;Robinson;A, G. |
| 國立成功大學 |
2024-09 |
Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)-SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
|
Garcia, Moreno;V;Oh;D-Y;Ryu;M, H.;Calvo;E;Garralda;E;Chung;W-P;Bai;L-Y;Laimito, Rojas;K, I.;Yildirim;O;Masciari;S;Mi;G;Wang;L;Kanlikilicer;P;Buday;B;Rharbaoui;F;Abbadessa;G;Dumbrava;E, E. E. |
| 國立成功大學 |
2024-09 |
Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours
|
Besse;B;Drilon;A, E.;Cho;B, C.;Camidge;D, R.;Neal;J;Lin;C-C;Liu;S, V.;Nagasaka;M;Kao;C-H, S.;Felip;E;Wekken, Van der;A, J.;Lin;C, C. C.;Bauman;J, R.;Gadgeel;S;Samant;M;Shen;J;Sun;Y;Zhu;V, W.;Upadhyay;V, A.;Lin;J, J. J. |
| 國立成功大學 |
2024-09 |
Precipitation of Auroral Electrons Accelerated at Very High Altitudes: Impact on the Ionosphere and a Possible Acceleration Mechanism
|
Imajo;S;Miyoshi;Y;Kazama;Y;Asamura;K;Shinohara;I;Shiokawa;K;Kasahara;Y;Kasaba;Y;Matsuoka;A;Wang;S, -Y.;Tam;S, W. Y.;Chang;T, -F.;Wang;B, -J.;Jun;C, -W.;Teramoto;M;Kurita;S;Tsuchiya;F;Kumamoto;A;Saito;K;Hori;T |
| 國立成功大學 |
2024-09 |
Initial results from a first-in-human study of AZD5335, a folate receptor a (FRa)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)
|
Shapira-Frommer;R;Sudo;K;Harano;K;Mileshkin;L;Perets;R;Song;M;Cohen;J;Huang;Y-F;Ambrose;H;Brier;T;Dosani;A;Fraenkel;P, G.;Kmieciak;A;Mitchell;P;Myers;C;Wang;J;Odegbami;R, I.;Sykes;A;Turner;S;Meric-Bernstam;F |
| 國立成功大學 |
2024-09 |
Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study
|
Toullec;C;Seo;S;Robinson;A, G.;Chou;H-H;Salman;P;Ghiringhelli;F;Ozyilkan;O;Rojas;C, I.;Sendur;M, A. N.;Tourneau, Le;C;Yen;C, J.;Aksoy;S;Ochsenreither;S;Ruiz;Yanez, E. P.;Rha;S, Y.;Shapira-Frommer;R;Liu;Q;Plessis, Du;M;Keenan;T;Hsu;C-H |
| 國立成功大學 |
2024-09 |
Association of biomarkers with response to first-line (1L) vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in advanced head and neck squamous cell carcinoma (HNSCC): Results from KEYVIBE-005
|
Seo;S;Calderon;B;Chou;H-H;Hsu;C-H;Salman;P;Ghiringhelli;F;Ozyilkan;O;Rojas;C, I.;Sendur;M, A. N.;Tourneau, Le;C;Yen;C, J.;Shapira-Frommer;R;Rha;S, Y.;Zhang;Y;Chen;C;Pena;C, E.;Keenan;T;Chen;Y;Dettman;E;Robinson;A, G. |
| 國立成功大學 |
2024-09 |
Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)-SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
|
Garcia, Moreno;V;Oh;D-Y;Ryu;M, H.;Calvo;E;Garralda;E;Chung;W-P;Bai;L-Y;Laimito, Rojas;K, I.;Yildirim;O;Masciari;S;Mi;G;Wang;L;Kanlikilicer;P;Buday;B;Rharbaoui;F;Abbadessa;G;Dumbrava;E, E. E. |
| 國立成功大學 |
2024-09 |
Updated safety and efficacy of ABSK-011 in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a phase I study
|
Chen;X-P;Yen;C, J.;Huang;P;Lin;C-C;Wang;J;Li;D;Li;Y;Gu;S;Li;G;Du;X;Sun;M;Dai;C;Qian;J;Liu;C;Liu;J;Zhuang;Z;Zhang;F;Kong;G;Cheng;Q;Cheng;A-L |
| 國立成功大學 |
2024-09 |
Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)-SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
|
Garcia, Moreno;V;Oh;D-Y;Ryu;M, H.;Calvo;E;Garralda;E;Chung;W-P;Bai;L-Y;Laimito, Rojas;K, I.;Yildirim;O;Masciari;S;Mi;G;Wang;L;Kanlikilicer;P;Buday;B;Rharbaoui;F;Abbadessa;G;Dumbrava;E, E. E. |
| 國立成功大學 |
2024-09 |
Updated safety and efficacy of ABSK-011 in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a phase I study
|
Chen;X-P;Yen;C, J.;Huang;P;Lin;C-C;Wang;J;Li;D;Li;Y;Gu;S;Li;G;Du;X;Sun;M;Dai;C;Qian;J;Liu;C;Liu;J;Zhuang;Z;Zhang;F;Kong;G;Cheng;Q;Cheng;A-L |
| 國立成功大學 |
2024-09 |
Real-world comparison of overall survival between BCMA - bispecific and CAR-T therapies in multiple myeloma
|
Song;J;Kim;G;Memon;R, S.;Chi;K-Y;Chang;Y;Mehta;A |
| 國立成功大學 |
2024-09 |
Initial results from a first-in-human study of AZD5335, a folate receptor a (FRa)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)
|
Shapira-Frommer;R;Sudo;K;Harano;K;Mileshkin;L;Perets;R;Song;M;Cohen;J;Huang;Y-F;Ambrose;H;Brier;T;Dosani;A;Fraenkel;P, G.;Kmieciak;A;Mitchell;P;Myers;C;Wang;J;Odegbami;R, I.;Sykes;A;Turner;S;Meric-Bernstam;F |
| 國立成功大學 |
2024-09 |
Enhancing Medical Imaging Reporting: a Multimodal Language Model for Automated Bone Scintigraphy Report Generation
|
Lu;H;Tsai;M |
| 國立成功大學 |
2024-09 |
On the Relationship between Thermomechanical Processing Parameters and Recrystallization Texture in AA1100 Aluminum Alloy
|
Yang;Hsin-Lun;Hsiao;Shih-Chieh;Chang;Chih-;I;Tseng;Tien-Yu;Chen;Po-Jen;Kuo;Jui-Chao |
| 國立成功大學 |
2024-09 |
Aspirin alleviates fibronectin-induced preeclampsia phenotypes in a mouse model and reverses fibronectin-mediated trophoblast invasiveness under hypoxia by regulating ciliogenesis and Akt and MAPK signaling
|
Tsai;Pei-Yin;Lee;Chih-;I;Tam;Hoi-Lam;Su;Mei-Tsz |
| 國立成功大學 |
2024-09 |
Precipitation of Auroral Electrons Accelerated at Very High Altitudes: Impact on the Ionosphere and a Possible Acceleration Mechanism
|
Imajo;S;Miyoshi;Y;Kazama;Y;Asamura;K;Shinohara;I;Shiokawa;K;Kasahara;Y;Kasaba;Y;Matsuoka;A;Wang;S, -Y.;Tam;S, W. Y.;Chang;T, -F.;Wang;B, -J.;Jun;C, -W.;Teramoto;M;Kurita;S;Tsuchiya;F;Kumamoto;A;Saito;K;Hori;T |
| 國立成功大學 |
2024-09 |
2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease--- Part I
|
Chao;Ting-Hsing;Lin;Tsung-Hsien;Cheng;Cheng-;I;Wu;Yen-Wen;Ueng;Kwo-Chang;Wu;Yih-Jer;Lin;Wei-Wen;Leu;Hsing-Ban;Cheng;Hao-Min;Huang;Chin-Chou;Wu;Chih-Cheng;Lin;Chao-Feng;Chang;Wei-Ting;Pan;Wen-Han;Chen;Pey-Rong;Ting;Ke-Hsin;Su;Chun-Hung;Chu;Chih-Sheng;Chien;Kuo-Liong;Yen;Hsueh-Wei;Wang;Yu-Chen;Su;Ta-Chen;Liu;Pang-Yen;Chang;Hsien-Yuan;Chen;Po-Wei;Jimmy;Jyh-Ming;Juang;Jimmy, Jyh-Ming;Lu;Ya-Wen;Lin;Po-Lin;Wang;Chao-Ping;Ko;Yu-Shien;Chiang;Chern-En;Hou;Charles, Jia-Yin;Wang;Tzung-Dau;Lin;Yen-Hung;Huang;Po-Hsun;Chen;Wen-Jone |
| 國立成功大學 |
2024-09 |
An exploration of operational efficiency, market efficiency, and sustainable development in the banking industry
|
Chen;Yu-Chuan;Lin;Tai-Yu;Chiu;Yung-ho;Yang;Ching-;I |
| 國立成功大學 |
2024-09 |
Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): Conditional survival and long-term safety in patients (pts) treated for ≥1 or ≥2 years in JAVELIN Bladder 100
|
Grivas;P;Park;S, H.;Voog;E;Su;W-P;Demey;W;Fong;P, C.;Garcia;J, A.;Jacob;N;Gerhold-Ay;A;Tyroller;K;Hoffman;J;Bellmunt;J;Powles;T, B. |
| 國立成功大學 |
2024-09 |
Does the primary location and metastatic timing of colorectal cancer influence the survival of patients with brain metastasis? A meta-analysis
|
Song;J;Yim;C;Tsai;T-C;Memon;R;Chi;K-Y;Gong;C;Lin;B-W;Lin;H-M;Chang;Y |
| 國立成功大學 |
2024-09 |
Initial results from a first-in-human study of AZD5335, a folate receptor a (FRa)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)
|
Shapira-Frommer;R;Sudo;K;Harano;K;Mileshkin;L;Perets;R;Song;M;Cohen;J;Huang;Y-F;Ambrose;H;Brier;T;Dosani;A;Fraenkel;P, G.;Kmieciak;A;Mitchell;P;Myers;C;Wang;J;Odegbami;R, I.;Sykes;A;Turner;S;Meric-Bernstam;F |
| 國立成功大學 |
2024-09 |
Updated safety and efficacy of ABSK-011 in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a phase I study
|
Chen;X-P;Yen;C, J.;Huang;P;Lin;C-C;Wang;J;Li;D;Li;Y;Gu;S;Li;G;Du;X;Sun;M;Dai;C;Qian;J;Liu;C;Liu;J;Zhuang;Z;Zhang;F;Kong;G;Cheng;Q;Cheng;A-L |
| 國立成功大學 |
2024-09 |
Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours
|
Besse;B;Drilon;A, E.;Cho;B, C.;Camidge;D, R.;Neal;J;Lin;C-C;Liu;S, V.;Nagasaka;M;Kao;C-H, S.;Felip;E;Wekken, Van der;A, J.;Lin;C, C. C.;Bauman;J, R.;Gadgeel;S;Samant;M;Shen;J;Sun;Y;Zhu;V, W.;Upadhyay;V, A.;Lin;J, J. J. |
| 國立成功大學 |
2024-09 |
Real-world comparison of overall survival between BCMA - bispecific and CAR-T therapies in multiple myeloma
|
Song;J;Kim;G;Memon;R, S.;Chi;K-Y;Chang;Y;Mehta;A |
Showing items 406-430 of 4992 (200 Page(s) Totally)
<< < 12 13 14 15 16 17 18 19 20 21 > >>
View [10|25|50] records per page
